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Abstract
Renal cell carcinoma accounts for about 3% of adult malignancies and 85% of neoplasms arising from the kidney. To identify
potential progression markers for kidney cancer we examined non-neoplastic and neoplastic kidney tissue from three
groups of patients, which represent different tumor stages (pT1, pT2, pT3) by a fluorescence two-dimensional difference gel
electrophoresis (2D-DIGE) approach combined with MALDI-ToF-MS/MS. Delta2D software package was used for gel image
based quantification and statistical analysis. Thereby, a comprehensive Principal Component Analysis (PCA) could be
performed and allowed a robust quality control of the experiment as well as a classification of the analyzed samples, which
correlated with the predicted stages from the pathological examination. Additionally for selected candidate proteins we
detected a correlation to the tumor grading as revealed by immunohistochemistry. On the 2D protein map 176 spots out of
989 were detected as at least 2-fold differentially expressed. These spots were analyzed by MALDI-ToF-MS/MS and 187
different proteins were identified. The functional clustering of the identified proteins revealed ten groups. Within these
groups we found 86 enzymes, 63 proteins of unknown function, 14 transporter, 8 peptidases and 7 kinases. From the
systems biology approach we could map many of these proteins in major pathways involved in remodelling of
cytoskeleton, mitochondrial dysfunctions and changes in lipid metabolism. Due to complexity of the highly interconnected
pathway network, further expression and functional validation of these proteins might provide new insights in kidney
cancer progression to design novel diagnostic and therapeutic strategies.
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Introduction
Renal cell carcinoma is the most common cancer of the kidney
and accounts for about 209 000 new cases per year worldwide and
102 000 deaths [1]. The curable therapy is a partial or total
nephrectomy and the clinical outcome depends on tumor stage
and grading. Unfortunately, about 20% of patients already show
metastases at diagnosis and additionally about 30% develop
metastases following surgery. In consequence of resistance against
chemotherapeutic agents and radiation therapy the therapeutic
options for these patients are very limited. Although rapid progress
has been made to understand tumorigenesis in renal cell
carcinomas and other tumor entities, the primary events leading
to dysfunction of the control of proliferation remain unclear.
Studies of genes involved in cell cycle control and even array
analysis studying the global gene expression pattern of neoplastic
cells in comparison with non-neoplastic cells led to the
identification of differentially expressed genes [2]. Using the
rendered gene expression pattern several research groups
identified differentially expressed genes, which could be used to
discriminate between non-neoplastic and neoplastic tissue and
which also correlated to the histological classification of the tumor
or even with the clinical outcome [3–5]. Considering that
regulatory dysfunctions can be caused not only by altered gene
expression but also by posttranslational modifications of proteins,
analyses of the proteome are of special importance to detect
disease-associated protein alterations [6]. Recently we and others
used these methods to identify differentially expressed proteins
comparing non-neoplastic and neoplastic kidney tissues [7–13].
Taking into account that tumor progression is reflected by
characteristic consecutive tumor stages we now studied neoplastic
tissues from kidneys belonging to different tumor stages and
gradings as well as non-neoplastic specimens, which may allow the
identification of progress markers or such of prognostic value.
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), a
powerful tool in proteomics used for protein separation and expression
profiling is one of the core technologies used in proteomics [14,15].
Protein expression analysis could lead to the characterization of
molecular events associated with cancer. The successful management
of human malignancies requires diagnostic and prognostic methods as
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be able to serve as a tool that provides useful information for all [16].
In the present study, we investigated the stage-related protein
alterations in kidney cancer from defined pathological character-
ized samples using 2D-DIGE [17] and MALDI-ToF-MS/MS for
protein identification. The differentially expressed proteins were
analyzed by Ingenuity Systems. Systems biology network analysis
might provide information about the potential role of proteins in
different regulatory pathways controlling kidney cancer progres-
sion and might predict new biomarkers for further validation using
Western blotting and immunohistochemical (IHC) approaches.
Materials and Methods
Ethics statement
The study was based on renal carcinoma patients diagnosed and
treated at the Department of Urology, University of Greifswald.
Tissue samples and patients data for this study were obtained and
used after ethics approval from the Ethics Committee at the
Medical Faculty of the University of Greifswald (III UV 12/03)
and in accordance with the declaration of Helsinki. We obtained
written informed consent of all participants.
Patient material
Representative samples from non-neoplastic and neoplastic
tissues were obtained immediately after nephrectomy. Kidneys
were sliced longitudinally along the largest diameter of the tumor.
From one half tissue samples were taken from the tumor and from
macroscopically non-neoplastic surrounding renal cortex tissue,
frozen in liquid nitrogen and stored at 280uC until use. From the
second half corresponding samples were fixed in formalin and
embedded in paraffin for subsequent immunohistochemistry and
examination bya pathologist.Furthermore,thepathological staging
was determined according to the latest TNM-classification [18] and
grading according to Fuhrman [19]. We analyzed in the 2D-DIGE
experiment one control and three tumor groups with different
stagings: pT1, pT2, pT3. Each group consisted of 9 samples. A
series of paraffin sections from 22 different samples containing
tumor sample with different gradings (76G1, 76G2 and 86G3)
were subjected to immunohistochemistry.
Protein isolation and labeling with CyDyes
The preparation of protein samples was performed with the
TRIzol
HReagent (Invitrogen, Karlsruhe, Germany) according to the
manufacturer’s protocol. Finally, the vacuum-dried protein pellet was
dissolved in sample buffer (8 M urea, 2 M thiourea, 4% CHAPS,
65 mM dithiothreitol, 40 mM Tris). Protein amounts were quantified
by the Bradford method [20]. Thequality of the samples for 2D-DIGE
was evaluated by mini 2D-PAGE (7 cm IPG strips). The protein
lysates were labeled with CyDyes according to the manufacturer’s
protocol for minimal labeling (CyDye DIGE Fluor minimal dyes, GE
Healthcare, Munich, Germany). In order to minimize dye-specific
labeling artefacts, Cy3 and Cy5-labeling patternsw e r es w a p p e d
among the same group of samples. An internal standard pool with
equal amountsofeach protein sample (25 mg) was used to reduce inter-
gel variation. The pooled internal standards were labeled with Cy2.
50 mg protein of each sample was labeled with 400 pmol of
corresponding dye on ice in the dark for 30 min. Reaction was
quenched with 10 mM L-lysine for 10 min under the same conditions.
Two-dimensional polyacrylamide gel electrophoresis
(2D-PAGE)
Samples were applied to IPG strips (pH 3-10 NL, 24 cm, GE
Healthcare, Munich, Germany) by in-gel rehydration. For DIGE-
gels a total amount of 150 mg protein and for preparative gels a total
of 700 mg protein were filled to a volume of 450 ml with rehydration
buffer (8 M urea, 2 M thiourea, 2% CHAPS, 15 mM dithiothreitol
and 0.5% IPG-buffer pH 3-10 NL [GE Healthcare, Munich,
Germany]). After rehydration overnight, isoelectric focusing (IEF)
was carried out at 20uC on a PROTEAN IEF Cell (Bio-Rad,
Munich, Germany) for a total of 55 000 Vhr. Subsequently, the
IPG strips were stored at -20uC or immediately soaked twice in a
solution containing 6 M urea, 2% SDS, 375 mM Tris-HCl
(pH 8.8), 20% glycerol and 1% dithiothreitol for the first, or 2.5%
iodoacetamide for the second step of equilibration. Strips were
placed on vertical SDS-PAGE gels and fixed with 1% agarose. As
tracking dye a few grains of bromophenol blue were added. SDS-
PAGEwas carried out using the PROTEAN plus Dodeca Cell (Bio-
Rad, Munich, Germany), with gels of 1.5 mm thickness and an
acrylamide concentration of 12.5%. Polyacrylamide gels for DIGE
were cast in low fluorescence glass plates. Electrophoresis was
performed with constant voltage (80 V) at 20uC until the dye front
reached the bottom of the gel. The complete device is protected
from light. After electrophoresis DIGE gel cassettes were washed
with ddH2O and wiped with dust free tissue paper. The Cy2
(Internal standard), Cy3 and Cy5 labeled proteins in each gel were
visualized by using a Typhoon 9400TM laser scanner (GE
Healthcare) at 100 microns by using different excitation and
emission wavelengths directly from gels between glass plates.
Optimal excitation/emission wavelengths for fluorescence detection
are 488/520 nm for Cy2, 532/580 nm for Cy3, and 633/680 nm
for Cy5. For preparative gels: 50 mg protein was labeled by Cy2 (as
internal control for gel matching) and mixed with 650 mg unlabeled
protein. After 2D separation the gel was scanned using a Typhoon
9400TM laser scanner and subsequently stained with Roti
H-Blue
(Carl Roth GmbH, Karlsruhe, Germany), a colloidal coomassie
brilliant blue G250 stain. Briefly, gels were fixed in 40% methanol,
15% acetic acid for at least 4 hrs and then immersed in colloidal
staining solution overnight. To remove background staining gels
were washed in 20% methanol.
Each sample was run in duplicate implementing a Cy3/Cy5 dye
swap thus enabling correction of dye-specific effects in the
subsequent statistical analysis.
Software and bioinformatic approaches
2D-gel image analysis was performed using Delta2D Software
version 4.0.8 (DECODON GmbH, Greifswald, Germany).
All gel images were matched with the Delta2D software and a
synthetic fusion gel was prepared using a union fusing option.
Final spot detection was performed on the fused gel.
The resulting spot pattern was assigned to each of the three
individual 2D-images (Cy2, Cy3, Cy5) of each of the gels in the
experiment. For further analysis, uniform spot quantification on all
gels and normalization were made according to the volume ratio
of corresponding spots detected in the Cy2 image of the pooled
internal standard sample using the internal standard module.
Student’s t-test was performed to assess the statistical significance
of differentially expressed proteins. Based on average spot volume
ratio, spots whose relative expression is changed at least 2-fold
(increase or decrease) between the stagings at 95% confidence level
(t-test; p,0.05) were considered to be significant. For subsequent
mass spectrometry analysis significant spot coordinates were
transferred to Coomassie stained preparative gel for spot picking.
The Hierarchical Clustering and the Principal Component
Analysis was performed corresponding to the Delta2D Software
protocol: The protein expression data were analyzed by
hierarchical clustering to find potential markers which can classify
all samples. The hierarchical clustering grouped both, samples (gel
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expression profiles and gel images by similarity. The cluster
hierarchy was shown in a tree display. The cluster composition
reflected the structure of the experiment, e.g. replicates and images
from the same sample gave similar expression levels and thus
ended up in the same cluster. The clustering was performed using
all expressed proteins of all 16 samples (quadruple replicates of
control, pT1, pT2 and pT3) included in the analysis set.
PCA was performed with the whole set of detected spots of all
gel images resulted in a three-dimensional visualization. The
information of all samples was linked together by an orthogonal
transformation and an overall pattern is presented in form of the
principal components.
After identification of proteins by mass spectrometry the
significant differentially expressed proteins were analyzed by
Ingenuity Pathway Analysis (IPA) to find the shortest pathways
between the identified proteins and to constitute molecular
partners involved in particular disease. A master global network
of all differentially expressed proteins (input objects) was suggested
according to published literature-based annotations, and then the
further sub networks were built from the master network to focus
activated experiments and/or pathways. Major hubs were
identified based on the connections and edges with in the network.
The heterogeneous set of the identified proteins was also analyzed
using gene ontology, which provides information about gene
function and cellular localization.
Preparation of peptide mixtures for MALDI-MS
Protein identification was performed as described earlier
[21,22]. Briefly, proteins were excised from Colloidal Coomassie
Brilliant Blue stained 2D gels using a spot cutter (Proteome
WorksTM, Biorad, Hercules, CA, USA) with a picker head of
1.5 mm diameter and transferred into 96 well microplates loaded
with 100 ml LiChrosolv
H water (Merck KGaA, Darmstadt,
Germany) per well. Digestion with trypsin and subsequent spotting
of peptide solutions onto the MALDI-targets were performed
automatically in the Ettan Spot Handling Workstation (Amer-
sham-Biosciences, Uppsala, Sweden) using a modified standard
protocol. Gel pieces were washed twice with 100 ml5 0 m M
ammoniumbicarbonate/50% (v/v) methanol for 30 min and once
with 100 ml 75% (v/v) ACN for 10 min. After drying 10 ml trypsin
solution containing 20 ng/ml trypsin (Promega, Madison, WI,
USA) in 20 mM ammoniumbicarbonate was added and incubated
at 37uC for 120 min. For peptide extraction gel pieces were
covered with 60 ml 50% (v/v) ACN/0.1% (w/v) TFA and
incubated for 30 min at 37uC. The peptide containing supernatant
was transferred into a new microplate and the extraction was
repeated with 40 ml of the same solution. The supernatants were
dried at 40uC for 220 min completely. Peptides were dissolved in
2.2 ml of 0.5% (w/v) TFA/50% (v/v) ACN and 0.7 ml of this
solution were directly spotted on the MALDI-target. Then, 0.4 ml
of matrix solution (50% (v/v) ACN/0.5% (w/v) TFA) saturated
with a-cyano-4-hydroxycinnamic acid was added and mixed with
the sample solution by aspirating the mixture five times. Prior to
the measurement in the MALDI-ToF instrument the samples were
allowed to dry on the target 10 to 15 min.
MALDI-MS
The MALDI-MS measurement of spotted peptide solutions was
carried out on a 4800 MALDI-ToF/ToF
TM Analyzer (Applied
Biosystems, Foster City, CA, USA). The spectra were recorded in
reflector mode in a mass range from 800 to 4000 Da with a focus
mass of 2000 Da. For one main spectrum 25 sub-spectra with 100
shots per sub-spectrum were accumulated using a random search
pattern. If the autolytical fragment of trypsin with the mono-
isotopic (M+H)+m/z at 2211.104 reached a signal to noise ratio
(S/N) of at least 10, an internal calibration was automatically
performed using this peak for one-point-calibration. Calibration
was performed manually for the less than 1% samples for which
the automatic calibration failed. Additionally MALDI-MS/MS
analysis was performed for the five strongest peaks of the MS-
spectrum after subtraction of peaks corresponding to background
or trypsin fragments. For one main spectrum 20 sub-spectra with
125 shots per sub-spectrum were accumulated using a random
search pattern. The internal calibration was automatically
Table 1. Clinicopathologic characteristics of patient samples.
Patient ID Gender Age pT pN M G
Co1 f 85 2 0 0 2
Co2 m 72 2 0 0 2
Co3 m 80 2 0 0 2
Co4 m 80 2 x 0 2
Co5 m 76 2 0 0 2
Co6 m 90 2 0 0 2
Co7 f 73 2 0 0 2
Co8 m 75 2 x 0 2
Co9 f 69 3a 0 0 2
pT1-1 f 61 1 x x 1
pT1-2 m 75 1 0 0 2
pT1-3 m 80 1 x x 1
pT1-4 m 58 1 x x 2
pT1-5 m 71 1 x 0 2
pT1-6 m 73 1 0 0 2
pT1-7 m 57 1 0 0 1
pT1-8 m 81 1 0 0 2
pT1-9 m 84 1 x 0 1
pT2-1 m 80 2 x 0 2
pT2-2 m 81 2 0 x 3
pT2-3 m 44 2 0 0 2
pT2-4 m 69 2 x 0 2
pT2-5 f 70 2 0 0 2
pT2-6 f 85 2 0 0 2
pT2-7 m 80 2 0 0 2
pT2-8 f 57 2 0 0 1
pT2-9 m 76 2 0 2 1
pT3-1 m 66 3a 1 1 3
pT3-2 f 80 3 1 1 3
pT3-3 m 72 3a 0 0 2
pT3-4 m 50 3b x 1 3
pT3-5 m 62 3b 0 1 2
pT3-6 m 66 3a 0 0 2
pT3-7 f 77 3a 0 1 2
pT3-8 m 73 3b 2 x 3
pT3-9 f 79 3a 0 0 2
The characteristics of the 9 control samples and 27 kidney cancer included
gender, age, TNM status and tumor grading. All samples were obtained from
the Department of Urology, University of Greifswald.
doi:10.1371/journal.pone.0021867.t001
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(M+H)+m/z at 175.119 or lysine (M+H)+m/z at 147.107 reached
a signal to noise ratio (S/N) of at least 5. After calibration a
combined database search of MS and MS/MS measurements was
performed using the GPS Explorer software (Ver. 3.6, Applied
Biosystems, Foster City, CA, USA) with the following settings: (i)
MS peak filtering: mass range from 800 to 4000 Da; minimum S/
N filter of 10; peak density of 50 peaks per range of 200 Da and
maximal 200 peaks per protein spot; mass exclusion list contained
background peaks and trypsin fragments with an exclusion
tolerance of 50 ppm (ii) MS/MS peak filtering: mass range from
60 Da to a mass that was 20 Da lower than the precursor mass;
peak density of 50 peaks per 200 Da and maximal 65 peaks per
MS/MS; minimum S/N filter of 10 (iii) database search: precursor
tolerance 50 ppm and MS/MS fragment tolerance 0.45 Da. Peak
lists were compared with the SwissProt database v56.1 human
taxonomy. Peptide mixtures that yielded at least twice a mowse
score of 56 for database results were regarded as positive
identifications.
Western blotting
Fifty microgram of protein were loaded per lane and separated
by 15% SDS-PAGE followed by transfer onto nitrocellulose
membrane. Blocking was carried out in 16Roti-Block solution
(Carl Roth GmbH, Karlsruhe, Germany). Membranes were
incubated with rabbit anti-Prohibitin (Abcam plc, Cambridge,
UK; 1:5000), rabbit anti-Peroxiredoxin-3 (self-made, 1:5000) and
rabbit anti-S100-A9 (Abcam plc, Cambridge, UK; 1:1000) in
TBST- 5% BSA solution overnight at 4uC. Excess antibodies were
removed by washing with TBST. Incubation with peroxidase-
conjugated secondary antibody (anti-rabbit IgG,1:5000 in 16Roti-
Block) was performed for 1 h at room temperature. After three
washes, the reaction was developed by the addition of LumiGLO
substrate (Cell Signaling Technology Inc., Danvers, MA, USA).
The emitted light was captured on X-ray film (CEA Deutschland,
GmbH, Hamburg, Germany). Western blotting for RPLP0
(BIOZOL Diagnostica Vertrieb GmbH, Eching, Germany) was
performed to verify equivalent protein loading.
Immunohistochemistry
Paraffin sections from 22 different samples containing tumor
tissue with different gradings (76G1, 76G2 and 86G3) were
subjected to immunohistochemistry. The used antibodies were the
same as for the Western blotting. The immunohistochemical
staining for prohibitin (1:100) and S100-A9 (1:100) was performed
on a Leica Bond
TM system (Leica Mikrosysteme Vertrieb GmbH,
Wetzlar, Germany) and for peroxiredoxin-3 (1:4000) a Bench-
Mark
HXT (Ventana Medical Systems Inc., Tucson, USA)
automated staining system was used. Prior to immunohistochem-
istry endogenous peroxidase activity was blocked. For prohibitin
antigen retrieval was performed by heating (epitope retrieval
solution pH 6.0). The primary antibodies were incubated for
16 min (prohibitin and S100-A9) and 32 min (peroxiredoxin-3)
respectively. Visualization was performed using the avidin-biotin
complex method. Photographs were taken on a Zeiss Axioskop 40
microscope equipped with a Nikon DS-2Mv digital camera.
Figure 2. Classification of differentially expressed proteins according to their cellular function. The pie charts display the classification of
the subset of differentially expressed proteins listed in Table S1 divided into 11 molecular functional categories (A) and into 16 biological processes
(B). Molecular functions regulated by the differentially expressed proteins classified by Gene Ontology.
doi:10.1371/journal.pone.0021867.g002
Figure 1. Representative 2-DE proteome map of kidney cancer. A 2D proteome map of kidney cancer tissue (fused image), pI range 3–10 NL,
12.5% SDS-PAGE is presented. The identified proteins, which are significantly altered were labeled with numbers. B Dual channel image analysis.
Differences in spot intensities were analyzed in all possible gel combinations. Each channel represents a fused gel image of all 4 technical replicates. C
Representation of the possible changes between tumor stages pT1, pT2 and pT3 with different maxima. Above the bars, the number of spots that
follow this trend is mentioned.
doi:10.1371/journal.pone.0021867.g001
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2D-DIGE analysis and mass spectrometry
We analyzed the proteome of kidney cancer pool specimens
from 27 cancer patients (pT1, pT2, pT3) and 9 corresponding
control tissues (Table 1) by 2D-DIGE in a pI range of 3.0–10.0
and molecular weight range between 10 kDa and approx.
140 kDa. In this range, 989 spots were clearly detected and
analyzed using Delta 2D statistical software tool for differential
protein expression. The average abundances of spots were
quantified and those with relative changes in abundance greater
than two times between at least two tumor stages (up or down) at
95% confidence level (p,0.05) were considered.
219 spots, significantly altered in their abundance among all the
samples included in the analysis set, were selected for further
identification. Interesting spots were excised from preparative gels
for protein identification by tryptic in-gel digestion and MALDI-
MS/MS analysis. Following a database search using the acquired
MS and MS/MS data 187 different proteins representing 176
spots were identified (Table S1). In several spots were identified the
same protein, probably due to post translational modifications. On
the other hand, some spots contained more than one protein.
Exemplarily we issued a proteome map of kidney cancer tissue
(fused images, pH 3-10 NL) which was shown in Figure 1A. The
numbered spots depict at least 2-fold differentially expressed
proteins. The dual channel image analysis showed differences in
spot intensities in all possible gel combinations (Figure 1B). Each
channel represented a fused gel image of all 4 technical replicates.
The differentially expressed spots have been divided into stage
related groups like maximum at pT1 (126 spots), maximum at pT2
(27 spots) or maximum at pT3 (23 spots). This principle distribution
was shown in Figure 1C illustrating the data from Table S1.
Classification of Differentially Regulated Proteins
In terms of cellular functions and processes, the proteins were
distributed into the categories (A) molecular function: ion channel
activity (3.3%), transporter activity (1.7%), translation regulator
activity (1.1%), transcription regulator activity (1.1%), enzyme
regulator activity (3.3%), catalytic activity (58%), motor activity
(2.2%), receptor activity (2.2%), antioxidant activity (1.1%),
structural molecule activity (14.4%) and binding (22.1%); (B)
biological processes: apoptosis (3.3%), transport (13.8%), system
process (10.5%), response to stimulus (12.7%), reproduction
(1.7%), metabolic process (65.7%), localization (1.1%), immune
system process (16%), homeostatic process (1.7%), generation of
precursor metabolites and energy (13.8%), developmental process
(14.9%), cellular process (25.4%), cellular component organization
(12.7%), cell cycle (5%), cell communication (12.2%) and cell
adhesion (1.7%) (Figure 2A and 2B).
Hierarchical clustering and Principal Component Analysis
The hierarchical clustering showed a comparison of all spot
values of all samples against each other and resulted in distribution
for all protein spots on first axis and a distribution of samples by
similarity on second axis. A section of those heatmap was shown in
Figure 3A. The columns represented the different samples (control,
pT1, pT2 and pT3 in quadruples) performed in dye swap
experiments and the rows indicated analyzed spots (total: 989).
The dendrograms represented the distances between the clusters.
All sample groups form distinct and separated clusters, respectively.
Figure 3. Hierarchical clustering and Principal Component Analysis. Principal component analysis can separate normal and tumor tissue. A
Partial representation of the unsupervised clustering (Euclidean Distance measure and the ‘average’ linkage) was performed using the log
transformed expression protein values of 16 samples (quadruple replicates of control, pT1, pT2 and pT3). The samples are shown vertically, the spots
horizontally indicated by ID numbers. The dendrograms represent the distances between the clusters. High expressions are coloured orange, the
lower ones in blue. B 3D-plot of the first three principal components of PCA from the protein expression data separates all analyzed samples. Each
point represents one sample with different replicates and dye swap, distribution of information with respect to differential expression between tumor
stages and control tissues. The output of the model indicates the existence of 4 classes differing significantly according to their separability. They
fitted to the analyzed sample groups: control, pT1, pT2 and pT3.
doi:10.1371/journal.pone.0021867.g003
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clustering together, (b) the dye swap of the replicates was clustering
clearly in between the same group, (c) control samples (co) were
clearly separated from tumor samples (pT1, pT2, pT3), and (d) pT1
cluster was separated from pT2/pT3 cluster.
These results had been affirmed also by the Principal
Component Analysis. PCA worked by taking spot intensities on
every gel image and assembling them into a vector. The gels from
different samples would be in separate regions of the resulting
diagram. Their coordinates could be analyzed in order to
determine which spots were contributing most to the variance,
making them candidates for protein identification and biological
interpretation. In Figure 3B the first three dimensions of highest
variances (principal component 1=51.1%, principal component
2=15.8%, principal component 3=11.9%, summary of the first
three components=78.8%) distinguished all analyzed samples in a
very impressive way: again, control samples were separated from
all tumor samples as well as a clear separation could be observed in
between the tumor stages.
Networks analysis of identified proteins by Ingenuity
Pathway Analysis
Pathways and networks, in that proteins derived from 2D-
PAGE using DIGE techniques (differentially expressed in kidney
cancer) are involved, were analyzed using Ingenuity Pathway
Analysis.
In conclusion of this analysis 187 proteins were classified
concerning top biological functions and top networks attached to
associated function. Among them 86 proteins related to cancer (p-
value 7.79E-14–2.40E-02), 117 to genetic disorder (p-value 1.21E-
10–2.40E-02), 79 to neurological disease (p-value 1.21E-10–2.40E-
02), 59 to skeletal and muscular disorders (p-value 1.21E-10–
2.40E-02) and 41 to gastrointestinal disease (p-value 7.95E-08–
2.09E-02).
The functional sub-networks were built using IPA from the
input proteins (Table 2). The networks would be assigned by a
different number of proteins. With identification based on the 2D-
DIGE analysis, we found a correlation between the described
proteins and our data of around 48%–69%. The most significant
sub networks were (A) Lipid Metabolism, Molecular Transport,
Small Molecule Biochemistry (24 proteins out of 36 proteins;
69%), (B) Cellular Assembly and Organization, Skeletal and
Muscular System, Development and Function, Tissue Morphol-
ogy (22 proteins out of 33 proteins; 67%), (C) Cellular Movement,
Hematopoiesis, Immune Cell Trafficking (21 proteins out of 35
proteins; 60%), (D) Genetic Disorder, Metabolic Disease,
Embryonic Development (21 proteins out of 34 proteins; 62%)
and (E) Lipid Metabolism, Small Molecule Biochemistry, Cancer
(16 proteins out of 33 proteins; 48%) which were represented in
Figure 4A–E.
Validation of selected candidates by
immunohistochemistry and Western blotting
Three candidates were selected for further validation: (a)
prohibitin, (b) thioredoxin-dependent peroxide reductase PRDX3
and (c) protein S100-A9.
In Figure 5A, selected gel regions and the quantification of 2D
spots were explicitly presented for the considered candidates. The
Table 2. Ingenuity Pathway Analysis networks of proteomic data and functional protein sub networks altered in kidney cancer.
No
a network
b described molecules
c
confirmed with this
analysis
d %
e
1 Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry 35 24 69
2 Cellular Assembly and Organization, Skeletal and Muscular System
Development and Function, Tissue Morphology
33 22 67
3 Cellular Movement, Hematopoiesis, Immune Cell Trafficking 35 21 60
4 Genetic Disorder, Metabolic Disease, Embryonic Development 34 21 62
5 Lipid Metabolism, Small Molecule Biochemistry, Cancer 33 16 48
6 Post-Translational Modification, Carbohydrate Metabolism, Nucleic Acid
Metabolism
34 15 44
7 Lipid Metabolism, Small Molecule Biochemistry, Nucleic Acid Metabolism 31 13 42
8 Cellular Development, Cardiovascular System Development and Function,
Cell Morphology
35 13 37
9 Cell Death, Cell Morphology, Connective Tissue Development and Function 34 13 38
10 Lipid Metabolism, Small Molecule Biochemistry, Genetic Disorder 29 12 41
11 Nucleic Acid Metabolism, Small Molecule Biochemistry, DNA Replication,
Recombination, and Repair
35 10 29
12 Carbohydrate Metabolism, Cell-To-Cell Signaling and Interaction,
Hematological System Development and Function
25 5 20
13 Endocrine System Development and Function, Small Molecule
Biochemistry, Lipid Metabolism
215 0
14 Cell Cycle, Reproductive System Development and Function, DNA
Replication, Recombination, and Repair
313 3
a network number.
bdescription of the network.
cnumber of described proteins in the network.
dnumber of proteins in the network confirmed by this approach in comparison to the described proteins.
epercentage of confirmation.
doi:10.1371/journal.pone.0021867.t002
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21867results from the 2D gel expression patterns were evaluated by
using standard Western blot analysis in a one-dimensional gel
system. The estimated protein amounts were depicted as columns
(Figure 5B). Immunohistochemical assessment with consideration
of tumor size (pT1, pT2, pT3) was supplemented by inclusion of
tumors belonging to different gradings (76G1, 76G2 and 86G3)
(Figure 5C). The intensity of the tumor staining was scored 1
(negative to weak), 2 (intermediate) and 3 (strong). In the case of
S100-A9 positive cells were counted in twenty visual fields
(Figure 5C, right; Table 3). The evaluation of the control tissue
proved to be complicated because of different proportions of
glomeruli, tubules and collecting ducts in the selected tissue slices.
For prohibitin two spots were identified with alternating
expression profiles: the spot 560 showed generally a weak
expression with a maximum at pT2 whereas spot 566 revealed a
decreased expression in all tumor stages in relation to the control.
In Western blot analysis the prohibitin antibody detected two
bands, whose molecular weight and expression level correlated
with the identified 2D spots (Figure 5A, 5B). In immunohisto-
chemistry the total amount of prohibitin seems to be not altered
stage-dependently (Figure 5C, upper lane). Additionally we
observed in our immunohistochemical studies a considerable
grading-dependent increase for total prohibitin.
Also PRDX3 as well as S100-A9 were identified in two spots,
each with similar expression profile. In contrast to the strong
PRDX3 expression in the control a continuous stage-dependent
decrease was observed in tumor samples.
A decrease in relation to the control was also indicated in the
Western blot. This diminishment was evident and confirms the 2D
data but was not definitely stage-correlated. Considering only the
tumor samples, the immunohistochemical estimation of PRDX3
revealed a maximum at pT2 as well as in G2 tumors. Concerning
S100-A9 protein the spot pattern displayed a very weak expression
in the control accompanied by a maximal expression at pT2,
which was also observed in the Western blot and histochemically,
whereas the grading dependence was increasing (Figure 5A, B, C).
Immunohistochemical evaluation of the kidney cancer tissue
sections exhibited prohibitin as localized in cells of the adjacent
renal parenchyma and in glomerular epithelial cells. PRDX3 was
detected in the tubulus epithelia with a stronger expression in the
distal part of the tubular system. S100-A9 was found in
inflammatory cells in blood vessels as well as in the interstitium
indicating tumor infiltration (Figure 5C).
Discussion
Inthepresentstudywecomparedtheproteomeofnon-neoplastic
and neoplastic renal tissues. In comparison to our previous studies
[7,8,13] we now extended the analysis to identify stage-related
protein alterations by using 2D-DIGE techniques and network/
pathway analysis. Compared to conventional 2DE, DIGE-based
proteomics with fluorescence labeling has many advantages such as
higher sensitivity, reproducibility with linear dynamic range for
better quantification, and less technical variations because of a
pooled control as internal standard. Internal controls affirm
respectable quality as has been demonstrated impressively by the
results of the Principal Component Analysis (Figure 3B).
To the best of our knowledge, we provide a comprehensive map
of kidney cancer within stage-related alterations of 187 proteins.
Compared to previous literature data [23–31], 93 proteins were
confirmed (Table S2). Differences between our results and other
previously published proteomic analyses could be attributed to
technical differences (i.e., the mass spectrometry approaches) and
the nature of the material analyzed (e.g., cell culture vs. tissue).
Other important factors to be considered are tumor heterogeneity
and the differences in histological types of the tumors analyzed
[27]. Nevertheless we could identify 94 proteins newly described in
relation to kidney cancer using the DIGE technique.
We observed in our studies most striking expression differences
for proteins involved in remodelling of the cytoskeleton,
mitochondrial dysfunctions and changes in lipid metabolism
(Table 3, Figure 4). Renal cell cancer mostly arises from the
proximal renal tubules. Cells of the proximal tubule rely strongly
on mitochondrial function to supply the energy for extensive
resorption mediated by Na
+/K
+ ATPases in the basolateral
membrane. As a typical metabolic pattern these cells produce ATP
from fatty acid oxidation and ketone body degradation, but
tumorigenesis demands a switch to glycolysis. The fact that tumor
cells are characterized by a specific energy metabolism is known
for a long time [32]. In the light of the hypothesis of Warburg it
was not surprisingly that we found typical enzymes of glycolysis
(HK, PFK, TPIS) up-regulated and in contrast enzymes and
structural proteins of the respiratory chain (NDUS2, COX5A/B,
QCR1/2, CYC, ATPA/B/G) and TCA cycle (CISY, DHSH,
IDHP) downregulated (Tabelle S1). These specific metabolic
alterations enable the tumor to grow under hypoxic conditions.
The benefit for the tumor is the prevention of oxidative stress,
because the mitochondrial oxidative phosphorylation is accompa-
nied by the production of reactive oxygen species. Additionally the
increasing acidification by high lactate production promotes
invasive tumor growth and metastasis [33,34]. We also observed
downregulation of typical b-oxidation enzymes (ECHM, Acyl-
CoA-DHG) which confirmed the dramatic metabolic alteration in
kidney cancer. The glucose dependency of most tumor cells
provides therapeutical approaches like pharmacological inhibition
of glycolysis or a carbohydrate reduced/ketogenic diet [35,36]. On
the other hand, antiglycolytic strategies seems to be promising
approaches to overcome chemoresistance in cancer cells [37],
since it is known that the treatment options in kidney cancer are
limited.
An important goal of our study was the comparison of tumor
tissues of different stages. We used this experimental strategy to
prove whether this procedure is able to identify stage-related,
differentially expressed proteins which may be useful as progress
markers or are of prognostic value. Considering this and the
apparent mitochondrial alterations in kidney cancer we selected
for further validation two mitochondrial proteins (prohibitin,
PRDX3) which we found as differentially expressed in our 2D-
DIGE approach, and the S100-A9 protein. More than 90% of the
Figure 4. Protein networks of differentially expressed proteins kidney cancer. Ingenuity Pathway Analysis was used to generate a network
of direct connections between all identified proteins with altered expression. Grey filled boxes are the differentially expressed proteins. Most
significant sub networks were shown in the figure. A Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry. 24 proteins out of 36
proteins in the network were confirmed with this analysis B Cellular Assembly and Organization, Skeletal and Muscular System Development and
Function, Tissue Morphology. 22 proteins out of 33 proteins in the network were confirmed with this analysis. C Cellular Movement, Hematopoiesis,
Immune Cell Trafficking. 21 proteins out of 35 proteins in the network were confirmed with this analysis. D Genetic Disorder, Metabolic Disease,
Embryonic Development. 21 proteins out of 34 proteins in the network were confirmed with this analysis. E Lipid Metabolism, Small Molecule
Biochemistry, Cancer. 16 proteins out of 33 proteins in the network were confirmed with this analysis.
doi:10.1371/journal.pone.0021867.g004
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e21867analyzed samples were classified as G2. Therefore, we additionally
tested histopathologically whether the behaviour of our candidates
is associated to the grading classification of the tumors as well.
Prohibitin has been functionally linked to diverse processes,
such as transcriptional regulation, cell proliferation, development
and mitochondrial function [38–40].
Prohibitin has been associated with various types of cancer.
Initially prohibitin was identified as a tumor suppressor with anti-
proliferative potential [41]. The role of prohibitin as tumor-
suppressor has still been controversially debated [38,42,43]. In
breast cancer cells siRNA mediated silencing of prohibitin was
found to increase cell proliferation [44]. But the fact that in
numerous cancer cells prohibitin has been found to be
overexpressed its role as a tumor suppressor remained doubtful
[45]. In other studies a prohibitin silencing correlates with reduced
cell proliferation and there are indications that prohibitin may
function as a cell survival or antiapoptotic factor [46–49].
As mentioned in the results we found prohibitin in two different
spots by mass spectrometry. Both spots revealed a conversely
expression profile. Indeed, the used antibody detected two bands
of approximately 30 kDa and 40 kDa, respectively. Most probably
the detected band at 40 kDa represents a larger post-translational-
modified protein. Many studies have indicated that prohibitin
undergoes multiple post-translational modifications, such as
phosphorylation, glycosylation, palmitoylation, ubiquitination
and others [50–52]. Such modifications could explain the shift
in molecular weight of the two spots and admits to speculate about
the consequences.
Work is in progress to identify the nature of this modification
and its stage-correlated physiological role. Considering only the
tumor staging the total amount of prohibitin did not seem to be
changed immunohistochemically. The fact that the prohibitin
antibody detects both forms (30 and 40 kDa) explains these
findings. Since we observed a grading-dependent increase for total
prohibitin, it could gain importance as a progression marker.
Alterations represented in network 3 (Figure 4C) including
PRDX3 and S100-A9 which were also selected for further
validation. PRDX3 is involved in redox regulation of the cell
and protects cells against oxidative stress-associated apoptosis, as
has been shown previously [53,54]. PRDX3 belongs to a protein
family of thiol-specific antioxidative enzymes whose members are
involved in the enzymatic degradation of hydrogen peroxide,
organic hydroperoxides, and peroxynitrite [53]. Oxidative stress
caused by reactive oxygen species is considered to have
tumorigenic potential. Aberrant expression of peroxiredoxins
was found in a variety of cancer entities [55]. Especially for
PRDX3 increased expression was found in human breast cancer,
lung cancer, mesothelioma and hepatocellular carcinomas [56–
59]. In the present study we could demonstrate a significant stage-
related downregulation of PRDX3 in tumor cells compared to
non-neoplastic tissue (Figure 5A). But there was no association
with tumor size in the Western blot (Figure 5B). Immunohisto-
chemical studies however weakly suggested a correlation to size
and grading (Figure 5C). Considering this PRDX3 showed only
less potential to become a progress marker. This is in agreement
with an earlier study where the authors found that only 23% of
kidney cancer revealed positive immunoreactivity for PRDX3
[60].
The S100-A9 protein is a member of the S100 protein family, a
group of multi-genic, calcium-binding proteins that are differen-
tially expressed in a wide variety of cell types [61]. S100-A9 is
mainly expressed by macrophages in acutely inflamed tissues and
in chronic inflammation, detected in peripheral blood leukocytes,
in neutrophils and granulocytes infiltrating the tumor tissue.
Increased S100-A9 levels were detected in various human cancers,
presenting abundant expression in neoplastic tumor cells as well as
infiltrating immune cells [62–65]. In addition to other proposed
functions, S100-A9 promotes NF-kB activation and has been
associated with tumor development, cancer invasion or metastasis
[61]. Mice lacking S100-A9 showed no obvious phenotype, they
Figure 5. Validation of selected candidates. Prohibitin, thioredoxin-dependent peroxide reductase PRDX3 and protein S100-A9 were analyzed
by immunohistochemistry. Western blotting is displayed in comparison to detailed information from the 2D-DIGE. A 2D-DIGE snapshots from fused
gel images for prohibitin (30 kD and 40 kD), thioredoxin-dependent peroxide reductase PRDX3 and protein S100-A9 with quantification data (bar
graph). B Protein quantification for prohibitin (30 kD and 40 kD), thioredoxin-dependent peroxide reductase PRDX3 and protein S100-A9 by Western
blotting, only representative blots were shown here. RPLP0 was used as loading control. C Immunohistochemistry of staging dependencies (pT1, pT2,
pT3) of G2 tumors (above). The bars represent semiquantitative quantifications of one representative sample. Immunohistochemistry depending on
tumor grade (G1, G2, G3; below). The bars represents semiquantitative quantifications of different samples (76G1, 76G2, 86G3).
doi:10.1371/journal.pone.0021867.g005
Table 3. Immunohistochemistry-semiquantitative
quantifications of selected candidates depending on tumor
grade.
prohibitin S100-A9 PRDX3
G1 25 7 2
G1 21 5 1
G1 2 130 2
G1 23 8 1
G1 15 0 1
G1 28 6 1
G1 12
mean 1,71 62,67 1,43
G2 37 9 2
G2 36 0 2
G2 32 5 3
G2 3 112 3
G2 32 2 3
G2 2 380 3
G2 3
mean 2,86 113,00 2,67
G3 3 350 3
G3 3 280 3
G3 3 220 1
G3 3 136 3
G3 3 154 3
G3 3 158 3
G3 141
G3 2 103 3
mean 2,57 150,71 2,43
The intensity of the tumor staining was scored 1 (negative to weak), 2
(intermediate) and 3 (strong). In the case of S100-A9 positive cells were counted
in twenty visual fields.
doi:10.1371/journal.pone.0021867.t003
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cancer they showed significantly reduced tumor incidence, growth
and metastasis [68]. If this could be confirmed in a renal cancer
model, S100-A9 would be a promising target to study tumor
progression. We observed a stage- and clearly grading-associated
increase of S100-A9. Nevertheless, further studies need to be
conducted to validate S100-A9 as a marker for tumor infiltration
or as a possible candidate with prognostic predictions concerning
tumor development.
In conclusion, the here established, comprehensive kidney
cancer map depicting stage-related alterations extends the list of
disease-associated proteins. Some of these candidates might be the
starting point for further research to understand tumor develop-
ment and to develop diagnostic or prognostic markers. For that
purpose a complex proteome approach using 2D-DIGE combined
with an extensive statistical data analysis and subsequent principal
component analysis has been shown to be appropriate.
Supporting Information
Table S1 Differentially expressed proteins identified in
kidney cancer sample. Stage-related alterations in kidney
cancer-Identification of protein targets with 2D-DIGE coupled
mass spectrometry. No. at Figure 1, spot ID on consensus master
2D gel; DB accession*, official SwissProt accession number;
Protein name; Protein Score; Ratio, ratio pT1 /control, ratio pT2
/control, ratio pT3 /control; Trends, max pT1 with 2 subgroups,
max pT2 with 2 subgroups, max pT3 with 2 subgroups,
x=mapping corresponds to the groups; Protein MW, theoretical
mass; Protein PI, theoretical isoelectric point; Peptide Count, total
number of peptides for identification using mass spectrometry;
Sequence coverage, sequence covarage in percent; Sequence
coverage ms ms, sequence coverage in percent defined by MS/MS
data; Sequence coverage ms ms sig, sequence coverage in percent
defined by significant MS/MS data; Ions score; Peptides with ions
score, number of sequenced peptides with an ion score; Peptides
above identity threshold, number of peptides above identity
threshold; Peptides above homology threshold, number of peptides
above homology threshold; Rms error, peptide mass error
tolerance. SwissProt database v56.1 human taxonomy; cut off
score.56 with p-value,0.05, search parameters: MS/MS ion
search, enzyme: trypsin, variable modifications: carbamidomethyl
(C), oxidation (M), peptide mass tolerance: 650 ppm, fragment
mass tolerance: 60.45 Da, max missed cleavages: 1. *all entries
contain _HUMAN extension.
(XLS)
Table S2 Comparison of the identified proteins from
the 2D-DIGE experiment with published data. All proteins
were listed by name. Different references were given, marked by
reference number. The last rows include a summary of earlier
described proteins and separate them from newly detected and
identified proteins by this approach. *DB accession: according to
SwissProt (all entries contain _HUMAN extension).
(DOC)
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